Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2012

View Archived Issues

New product has antidiabetic and antiobesity effects in various animal models

Researchers provide further data on briakinumab efficacy

Addex provides promising topline data from phase IIa trial in levodopa-induced dyskinesia

Gene expression-based MAMPS for the prognosis of breast cancer

Novel naphthoquinones designed in China

Novel GPR119 receptor agonists prepared by Lupin

First-in-human trial of H1N1 influenza vaccine using iBioLaunch technology completed

Taisho presents novel sodium/glucose cotransporter 1 inhibitors

New PUFA metabolites patented by University of Tokyo

Phase I trial commences for candidate ADHD drug

NicOx enters option agreement for acquisition

Corcept Therapeutics announces launch plan

CSL prepares novel humanized IL-3R-alpha-directed antibodies

MDCO-216 as a new reverse cholesterol transport inducer

New monoamine reuptake inhibitors patented

New ICAM-1-targeted antibodies disclosed by MedImmune

Immunovative Therapies patents novel Th1/killer cells

Ajinomoto set to begin marketing certain Marzulene formulations in Japan

Starpharma launches two pivotal phase III VivaGel studies

Biotest reports promising preclinical data on BT-062

Daiichi Sankyo seeks line extension for denosumab in Japan

Daiichi Sankyo to develop narcotic analgesic for Japanese market

FDA committee issues recommendation for Marqibo

Emergent BioSolutions receives NIAID grant to advance TB vaccine candidate

Scottish university receives grant to investigate spread of leukemia in the blood

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...